uro-rESumoS brasil silva neto Doutor em Medicina: Ciências Cirúrgicas Universidade Federal do Rio Grande do Sul Serviço de Urologia Hospital de Clínicas de Porto Alegre U. S. Surveillance, Epidemiology, and End Results Milton berger Professor Adjunto de Urologia da Universidade Federal do Rio Grande do Sul im C. HU iangmei gU tUart r. lipsitz Jama. 2009; 302(14):1557-1564
- A |
J |K |
U |V |
South texas project selects sargent & lundy as owner's engineer
FOR IMMEDIATE RELEASE
CONTACT: Kelly Cripe
SOUTH TEXAS PROJECT SELECTS
SARGENT & LUNDY AS OWNER’S ENGINEER
STP moves forward on construction of two additional nuclear reactors
Wadsworth, Texas (May 14, 2007) – On track to be among the first nuclear construction in the
United States in nearly 30 years, The South Texas Project selected Sargent & Lundy LLC, a
leading engineering consulting firm, as its owner’s engineer to assist in the plant’s proposed
“Sargent & Lundy’s robust, multi-disciplined engineering staff will provide the depth we need.
Sargent & Lundy is an excellent engineering and project management organization with a proven
track record. Their seasoned managers and employees with nuclear construction experience and
construction management skills will complement STP’s existing team of experts.” said Kevin
Richards, STP’s group vice president for Units 3 and 4.
First announced in June 2006 by NRG Energy, an owner of STP, the expansion project will involve
the construction of two additional nuclear reactors, Units 3 and 4, to STP’s two existing reactors.
For more than three years, STP has led the U.S. in electricity production by a two-reactor facility.
Additionally, STP’s Unit 2 has led the nation’s 103 reactors in electricity production and is the third
highest producing reactor in the world. With the additional generation capabilities provided by two
new reactors, STP will double its capacity to provide safe, reliable and environmentally protective
electricity to approximately two million homes.
“Our first priority is to continue the safe and reliable operation of Units 1 and 2. We will continue
that same level of excellence by setting the industry standard in the licensing and construction of
new units. Adding Sargent & Lundy to our team will help greatly in achieving that objective,” said
STP President and CEO James Sheppard.
"We appreciate STP’s confidence in the high quality of our nuclear engineering capabilities and we
are pleased to support their vision to the continued production of environmentally sound, affordable
and safe electricity," said Bud Wendorf, Sargent & Lundy Chairman and CEO.
Sargent & Lundy will be managed directly by STP’s engineering staff and will begin work on the
expansion project immediately.
“We will work closely with Sargent & Lundy and will value their counsel on major project decisions
and direction. We are looking forward to a long-term partnership with this firm,” stated Richards.
STP SELECTS SARGENT & LUNDY AS OWNER’S ENGINEER…/add1
To find out more about the South Texas Project, visit www.stpnoc.com
About the South Texas Project
STP supplies power to customers in Houston, Austin, San Antonio, Corpus Christi and surrounding
areas. The plant is managed by the STP Nuclear Operating Company and is owned by NRG Texas
LLC, CPS Energy and Austin Energy. STP's twin reactors produce nearly 2,600 megawatts of
electricity, enough to power approximately two million homes.
About Sargent & Lundy
Sargent & Lundy LLC is a worldwide leader in professional services for the electric power industry and has been dedicated exclusively to serving energy business and energy intensive clients for 116 years. The firm provides comprehensive engineering, energy business consulting and project services for new and operating electric power plants and power delivery systems. For more information, visit www.sargentlundy.com.
Efficacy and safety of prophylactic intracameralKazuki Matsuura, MD, Teruyuki Miyoshi, MD, Chikako Suto, MD, Junsuke Akura, MD,PURPOSE: To report endophthalmitis rates after cataract surgery and the incidence of complica-tions after intracameral moxifloxacin injection. SETTING: Nineteen clinics in Japanese institutions. DESIGN: Retrospective survey cohort study. METHODS: The number of surgeries